News Conference News ACC 2022 POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery Todd Neale April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19 Todd Neale March 25, 2022
News Daily News REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19 Todd Neale March 22, 2022
News Daily News Antithrombotics Not Worth the Risk During Endovascular Stroke Therapy Todd Neale March 07, 2022
News Daily News Skipping Low-Value Cardiovascular Care Could Save Billions: AHA Michael O'Riordan March 01, 2022
News Daily News Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis Yael L. Maxwell March 01, 2022
News Daily News Fewer Diabetic Complications Seen When NOACs Given for AF L.A. McKeown February 22, 2022
News Daily News Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis Michael O'Riordan February 18, 2022
News Conference News ISC 2022 Tenecteplase Feasible Up to 24 Hours After Stroke Todd Neale February 15, 2022
News Conference News ISC 2022 ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis Todd Neale February 10, 2022
News Daily News Optimal Medical Therapy for Stable Angina: Which Drugs? How Long? Michael O'Riordan January 25, 2022
News Daily News DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis L.A. McKeown January 20, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News Shorter Anticoagulation an Option for Young Patients With Provoked VTE Todd Neale January 11, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022
News Daily News Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S Caitlin E. Cox January 07, 2022
News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021